MENU
Aim higher

SUBERB

Super Biased Ligands for Treatment of Type II Diabetes

We have very exciting results showing that we can develop compounds, “super biased ligands”, that simultaneously stimulate glucose uptake in muscle and brown fat through a novel insulin independent signalling pathway. The compounds radically reduce blood glucose levels in rodent diabetes models and our goal is to develop them to a preCD for the treatment of type 2 diabetes and forge a business alliance with a pharmaceutical company.
Acronym: 
SUBERB
Project ID: 
10 635
Ranking: 
102
Cut-off: 
5
Start date: 
01-09-2016
Project Duration: 
36months
Project costs: 
1 926 440.00€
Technological Area: 
Pharmaceutical Products / Drugs
Market Area: 
Therapeutic